RecruitingPhase 4NCT06271538

Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome

A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)


Sponsor

EP Plus Group Sdn Bhd

Enrollment

60 participants

Start Date

Oct 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Skal Pro for people with colonic disease, colonic diseases, functional, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTSkal Pro

One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS

OTHERPlacebo

One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet


Locations(1)

Hospital Universiti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06271538


Related Trials